Though a population of the HER2/ERBB2 subtype may harbor innate resistance to HER2 inhibitors, or a subset of other subtypes may show response, the large enrichment within the HER2/ERBB2 subtype suggests the accurate prediction of responders to HER2 inhibition within breast cancer patients. This evidence concerns the gene ERBB2 and breast cancer.